We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.50 | 12.00 | 13.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.50 | 32.57M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2024 06:55 | So strange, why post drivel and use multiple Aliases including Arthur lame stocks. | muffster | |
22/4/2024 23:03 | Good evening, all my friends I have been absent for a while. Unfortunately, I just got released from prison. I was wrongly accused of robbing the bankrupt Natwest bank; I was not near the branch. Anyway, it was proven by the appeal court that some overzealous copper stitched me up. My dad kicked me out of his mansion in Richmond, and now my mum is kicking him out of the place. I am so happy. I will be gambling all the money I have, which my departed gran left me. Hopefully, I can jet off with my GF to Sydney and never work. I will put all on this dead duck AGL at 0.5p for the dead cat bounce to 6.2p | deadshot is back | |
22/4/2024 22:32 | supernumerary, that was my take from what was said between 8.01 and 8.20 about enquiries from people saying "they have developed their own bespoke antibody staining processes but they like the slide thing". So at a later stage as well as being sold as part of the kits, it might become a stand alone product as well? | pj84 | |
22/4/2024 14:39 | One of Newlands better performances IMO (and I have been critical in the past). So sales team… ‘distributors beginning to find their feet and beginning to make some sales’ Could mean anything but I have to hope so me sales will be announced with the quarter results. (At least one!) (System that is not cartridge!) | gspanner | |
22/4/2024 12:50 | Havinthelasttoast 28 Oct '23 - 11:24 - 20507 of 23843 Ffs boys they just got approval a year ago, you think medical professionals move quickly to widely adopt a new way of working. Do you suppose the two new senior hires decided to tarnish their careers by joining a company and product with no future.Newland is thinking big. If he wanted to milk the company he wouldn't hire a global team and have cash burn of 20m per year ya daft mugs. The safe route to him was be tight with his 22m and build slowly. They are all in, and fully committed and he will lose all if he doesn't deliver.Ya daft penny punters with timescales of a day. | zeus19 | |
22/4/2024 12:46 | B - thanks again. They must be world experts in microfluidics. I wonder if that could be commercialised in its own right? | supernumerary | |
22/4/2024 12:40 | admit 9p placing is a bit of a ramp More likely to be 6p going by the trading and price action. Sorry | havinthelasttoast | |
22/4/2024 11:52 | Main course not yet served.Nomad in-tray is full and signing them off one by one. | atmysignal | |
22/4/2024 11:50 | Further to my 23858, Andrew Newland explains all in new proactive interview:- | bermudashorts | |
22/4/2024 11:29 | Every penny rise is sold into. Everyone trying trying to trade their average down lol | robizm | |
22/4/2024 11:03 | Whilst having been critical of the lack of early commercialisation (I.e why were the ducks not already in a row given how protracted FDA made the process) I have never lost my belief in either the medical (most important) and thus related commercial value of the products and this still hold every single share purchased pre FDA plus one small top up. Let’s hope and pray this is the start of a small snowball about to go over the top of a very large glacier ! | millwallfan | |
22/4/2024 09:44 | @gspanner gets it: In-house testing has shown that STANDARD laboratory TECHNIQUES, used WORLDWIDE, result in a high rate of CELL LOSS (>50%) and cause DAMAGE to CTCs. ?Cell Keep REDUCES COSTS by concentrating the CTCs into a smaller area on the slide, thereby LIMITING the quantity of HIGH COST antibodies and imaging TIME required to identify and analyse cells.- NO Contracts NO contracts NO contracts - is all I hear the negative nancy cry about - AGL maybe building out their services business (very professionally I might add) but you underestimate the PRODUCT side imo.- @gspanner was thinking the same as I - AGL have just unlocked a 'critical need' for the entire WORLDWIDE community who analyse CTCs including researchers, large pharma etc. ?As @gspanner eluded to - Sales of Cell Keep slides alone - what is that worth? I agree, certainly more than todays Market Cap. ?The fact AGL plan to sell it as part of kit - Portrait+ - says to me only one thing... Market Domination (Gold Standard). User buys a kit, has everything they need and instructions to follow - simplicity for the end user who now has a higher rate of CTCs than anyone else in the WORLD who opts to use an alternative product. | 5oletrader | |
22/4/2024 09:16 | Yes, the posts Angle are recruiting to show a big push towards monetisation and I believe also indicate that some good progress has already been made (we may hear more about that soon with results). Unlike some companies I think Angle has very sensibly taken time to develop technology that actually works, to establish good data, and to secure regulatory protections. The company is currently very undervalued, but that won't last for long now that we are into this exciting phase. | spa362 | |
22/4/2024 09:08 | Excellent. Things seem to be aligning on Her2. Would be fantastic to see that progress now. | bagpuss67 | |
22/4/2024 09:01 | Bagpuss, These patents are all about commercialisation. The breast cancer clinical trial used for FDA approval highlighted that CTCs captured by Parsortix were being lost during transfer from the casette to slides for downstream analysis. It was a weakness that needed fixing. So Angle have gone away and developed the Cellkeep slide to reduce this loss which in turn will increase the sensitivity of Parsortix. Good to see. | bermudashorts | |
22/4/2024 08:33 | ALS. Aren't they critically dependent on the product sales and pharma services cashflow to mitigate the extent of the raise needed and attendant dilution? | bagpuss67 | |
22/4/2024 08:23 | Spa362 Have you looked at the detailed job descriptions of those vacancies? The Impression I got from reading them is that pharma services is starting to take a back seat with a real drive towards obtaining further regulatory approvals and actually getting Parsortix into the clinic. | arthur_lame_stocks | |
22/4/2024 08:21 | Take a day off fake bones. | robizm | |
22/4/2024 08:15 | This mornings RNS an attempt to prep the ground for an upcoming cash placement!..pretty obvious really! Looks like it's back fired share price in decline now! | bones699 | |
22/4/2024 08:03 | I would agree Bagpuss though I would strongly suspect this is a result of many years work and also critical to the success of parsortix analysis in any event. If you can sell it to every else in the tumour cell space (if it becomes the ctc fixing gold standard) then it’s probably worth more than the current mcap! | gspanner | |
22/4/2024 08:02 | Great news! BUY | philjeans | |
22/4/2024 07:30 | Yes. That's an interesting quote. Although I do wonder if they should try and remain/be laser focussed on a few things and not open up another area. I don't think they will as they appear to be putting a lot of effort into commercialising what they have. Even prostate and Ovarian are in the long grass | bagpuss67 | |
22/4/2024 07:30 | It really is excellent news that helps to set Angle apart from the competition. Also nice to see active recruitment to a number of vacancies - suggests a very exciting time at the company upcoming. Feels like we are on the move | spa362 | |
22/4/2024 07:23 | Perhaps there'll be additional info to follow on the nature & significance of the other cell types from various body fluids as mentioned by Karen Miller. | gooosed |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions